

<p><b>Industry:</b> Drug Development, antiviral drugs  <b>Established:</b> November 2003  <b>Shareholders :</b> Founders, Biotech private investors, Private US investors  <b>Location:</b> Incorporated and headquartered in Paris, France. Spin-out from Pasteur Institute.  <b>Equity raised:</b> €3.2 M  <b>Employees:</b> 7 FTE's</p>	<p><b>Investment highlights: Five reasons why Anaconda will succeed:</b></p> <ul style="list-style-type: none"> <li>• Experienced management team and distinguished Scientific Advisory Board</li> <li>• Widely applicable new drug discovery platform based on blocking protein/protein interactions, particularly suitable for viral diseases</li> <li>• First result of new platform is a novel approach to block Human Papillomavirus (HPV) replication with a First-in-Class candidate drug ready for Phase I trials in the condyloma indication</li> <li>• Strong intellectual property protection</li> <li>• Initial HPV drug targets a large market opportunity with limited competition</li> </ul>
--	---

**OVERVIEW:**

Anaconda Pharma ("Anaconda") has developed a proprietary technology platform that allows to discover drugs that inhibit protein/protein interactions ("PPI"). The Company has initially applied its technology to develop drugs to treat Human Papillomavirus ("HPV")-related diseases; in particular condyloma (anogenital warts) caused by HPV 6 or 11. Anaconda is at the late pre-clinical stage of development of AP611074, its selected drug candidate for the topical treatment of condyloma and is seeking to raise financing to complete Phase I trials. Anaconda originated in The Pasteur Institute and UC Berkeley and is incorporated and headquartered in Paris, France.

**Technology Platform and First Products**

Anaconda's unique technology platform is aimed at identifying small molecules that disrupt PPI, which makes it possible to address a major new class of pharmaceutical drug targets. PPI have been unexploited to date due to the difficulty of recognizing drug'able hot-spots on the large surface areas of proteins. Anaconda's discovery platform integrates proprietary cell-based assays for drug screening and evaluation, together with structural modeling and chemo-informatic analysis, which considerably reduces the "hit to lead" drug development process for PPI targets.

The first products of Anaconda's technology platform target HPV, which is the world's most common sexually transmitted infection. A small molecule drug platform to treat the broad range of HPV infections represents a significant economic opportunity, especially as most indications are poorly treated.

**Intellectual Property**

The Company has a strong IP position. Anaconda's operations are not constrained by any upstream proprietary technology (Cabinet Regimbeau). French and international PCT patent applications covering new chemical series have been filed by Anaconda in 2006, 2007, 2008 and 2009. Prior art and written international search opinion (EPO) concluded that Anaconda's compounds are novel, inventive and patentable.

**Product Status**

The Company is at the late pre-clinical stage of development for AP611074, its selected drug candidate to treat condyloma. Several kg of cGMP AP611074 ready for clinical studies are available and topical formulation is ongoing, with several creams and ointments already developed. In testing to date, AP611074 and its back-up compounds demonstrate no dose limiting toxicity on human reconstructed skin, no sensitivity (skin reactions) in *in vivo* local tolerance studies on rabbits, no systemic toxicity in rats upon iv injection, and no genotoxicity nor mutagenicity on Ames and  $\mu$ Nucleus studies. AP611074 can be also developed as an oral drug for an additional indication, Recurrent Respiratory Papillomatosis - RRP, an orphan disease.

**Competition Advantages**

(1) Novel drug targets - PPI, with a large range of therapeutic indications; (2) Proprietary screening assays; (3) Proprietary high resolution crystallographic structures & in-silico modeling; (4) Novel and patented lead chemical series; (5) A first-in-class condyloma drug candidate and back-up molecules, ready to enter pre-clinical regulatory studies and clinical trials.

**Investment**

Anaconda has raised a total of €3.2 M since its inception in 2003 and continues to benefit from an additional €1.6m in grant funding.

The Company is seeking funding to complete clinical development of topical AP611074 up to Phase IIa in the condyloma indication and to further develop its pipeline.

**KEY MANAGEMENT**

**Highly experienced industry executives:**

**Marta BLUMENFELD, Ph.D.**

**CEO and Co-Founder**

Dr. Blumenfeld has 18 years executive management experience in biotech industry. Prior to founding Anaconda, Dr. Blumenfeld was VP Genomics Operations for Genset.

**Prof. Moshe YANIV, Founder**

**CSO and Co-Founder**

Prof. Yaniv is an international expert in HPV and Virology. He was Director of the Gene Expression and Disease Lab in the Pasteur Institute and Research Director (Extraordinary Class) at CNRS.

**Catherine FAURE.**

**CFO**

C.Faure has 18 years experience in finance & administration management in biotech/high tech, in France, US and Japan. Prior to Anaconda she worked as CFO for Genset and LTU Tech/JASTEC.

**Christian POLICARD.**

**Business Development**

Dr Policard is former Executive VP of Sanofi in charge of Diagnostic, Agro-Veterinary and Capital Development. He is also a former Executive VP of Institut Pasteur in charge of Technology transfer.

**Delphine COMPERE, Ph.D.**

**Head of Medicinal Chemistry**

Dr. Compère has 13 years organic & medicinal chemistry experience in pharma and biotech industry. Prior to Anaconda she worked for Cerep and Pfizer.

**Anaconda's SAB includes distinguished scientists and drug development experts:**

**Prof. Moshe YANIV, Founder (I. Pasteur)**

**Chairman of the Scientific Advisory Board**

**Prof. Michael BOTCHAN, Founder (UC, Berkeley)**

Division Head, Biochem. and Mol. Biol., UC Berkeley. Expert in eukaryotic DNA replication and protein structure.

**Prof. Olivier CHOSIDOW (Tenon Hosp, Paris)**

Clinical Dermatology, AFSSAPS/EMEA expert

**MILESTONES**

- 2003 Company foundation
- 2006 Condyloma and RRP candidate selection
- 2007-2009 Preclinical development
- 2010 Phase I/II condyloma

**Contact:**

**Marta Blumenfeld, CEO  
 Anaconda Pharma**

11, rue Watt – 75013 Paris, FRANCE

[mblumenfeld@anacondapharma.com](mailto:mblumenfeld@anacondapharma.com)

Tel: +33 1 75 57 86 54

[www.anacondapharma.com](http://www.anacondapharma.com)

JUNE 2009